Full-Time
Posted on 6/29/2025
Global provider of medical care products
$68k - $93.5k/yr
No H1B Sponsorship
Highland Park, IL, USA
In Person
Bachelor's
See people who can refer or advise you
Baxter International produces medical products and equipment used in hospitals and blood banks. Its innovations include sterile IV solutions and blood-storage technologies, such as the Transfuso-Vac that extended blood shelf life and a plastic blood storage container. The company differentiates itself through a long history of sterile manufacturing, blood-storage breakthroughs, and strategic acquisitions that expand its product portfolio and scale. Its goal is to provide reliable, safe medical products that support patient care and hospital operations worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Deerfield, Illinois
Founded
1931
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Parental Leave
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Commuter Benefits
Mental Health Support
Zoetis names Saccaro CFO, chief operating officer. The basics: * Saccaro will join Zoetis as CFO, COO Aug. 17 * Newly created role includes oversight of manufacturing, supply operations * Current CFO will serve as special advisor to the CEO through early 2027 * Zoetis reported $2.5B in Q2 2026 revenue Zoetis Inc. has appointed James (Jay) Saccaro as executive vice president, chief financial officer and chief operating officer, effective Aug. 17, 2026. The Parsippany-headquartered animal health company announced the new hire Aug. 6. Zoetis also said it's a newly created position. Saccaro will take over responsibilities from Wetteny Joseph, who will remain with the company as a special advisor to CEO Kristin Peck until early 2027. According to Zoetis' executive team page, Joseph's title is executive vice president and CFO. Saccaro joins Zoetis from GE HealthCare, where he most recently served as vice president and CFO. At that company, Saccaro led initiatives across sectors such as finance, accounting, new product planning, R&D prioritization and capital allocation, according to Zoetis. Prior to GE HealthCare, Saccaro held various financial leadership positions at Baxter International Inc., Hillrom, Clear Channel Communications and The Walt Disney Co., according to his LinkedIn profile. New position. "We are excited to welcome Jay to Zoetis as we prepare for our next wave of innovation-driven growth," Peck said in a statement. "Jay brings a unique combination of skills to this newly created leadership position. He is a seasoned finance executive with 12 years of CFO experience at some of the world's leading healthcare companies and has proven expertise in successfully developing and executing company-wide strategic initiatives." Peck added that responsibilities of the expanded position will include: * Strengthening the company's global manufacturing and supply operations * Enhancing supply chain and distribution performance * Driving greater operational agility Saccaro said he was "thrilled to join the world's leading animal health company," adding that there was "tremendous runway to build on" Zoetis' legacy. "From the company's deep innovation pipeline to its products that have built and defined categories in the industry, Zoetis is an exceptional business grounded in a deep commitment to setting new standards for the future of animal care." 'A challenging quarter' Peck also thanked Joseph "for his strong leadership, partnership, and many important contributions since joining the company five years ago." In his final earnings update posted on LinkedIn Aug. 6, Joseph said, "I want to recognize our colleagues, who remained focused on delivering for our customers despite a challenging quarter." In the video, Joseph noted that "results this quarter fell short of our expectations," adding that, on an organic operational basis, Zoetis' revenue declined 1% and adjusted net income declined 2%. The company's quarterly report noted revenue of $2.5 billion for the second quarter of 2026. Breaking down results across its U.S. and international segments: * U.S. segment revenue: $1.3 billion, decreasing 7% relative to Q2 2025 * International segment revenue: $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with Q2 2025 Joseph said challenges such as declining veterinary visits and greater pet owner price sensitivity placed pressure on the companion animal industry. However, he said the company was "responding with urgency and focus." He added on the post, "I close this chapter with confidence in Zoetis' people, portfolio and pipeline. The work ahead is clear, and the company has the talent and capabilities to execute and create long-term value."
Will operational challenges continue to negatively impact Baxter's second. Baxter International (BAX) is scheduled to report second-quarter 2026 earnings before the U.S. stock market open on July 30. In the prior-year quarter, the company's earnings missed the Zacks Consensus Estimate by 16.13%. Over the past four quarters, BAX has beaten estimates in two quarters and missed them in two quarters, by an average of 3.12%. The market consensus is for revenue to be $2.84 billion, down 0.6% from the previous year. Earnings per share are expected to be $0.36, down 39% from the previous year. Its model projects that, at constant exchange rates, total revenue from continuing operations will decline 2.5% to $2.79 billion. Adjusted earnings per share are expected to decline 39% to 36 cents. Baxter expects a slight improvement in its second-quarter results, but persistent efficiency gaps, cost inflationary pressures, and the ongoing suspension of high-volume infusion pump (LVP) shipments could constrain growth. Following the release of its first-quarter results, management reiterated its full-year outlook, stating that second-quarter profits are likely to remain flat compared to the first quarter, with only a slight increase in sales, and that a more significant recovery is expected in the second half of the year. While demand remains strong in end markets across various industries, project execution challenges and difficulties in year-over-year comparisons are expected to negatively impact profitability. In the Medical Devices and Therapies (MPT) segment, performance is likely to remain mixed. The Advanced Surgical segment should continue to outperform other segments due to strong global demand for hemostatic agents and sealants, as well as significant surgical volumes. However, the Infusion Therapies and Technologies segment may remain under pressure due to factors such as ongoing suspensions of Novum LVP device shipments and installations, declining infusion pump sales, and normalization of IV infusion demand following the expansion of the distribution network impacted by Hurricane Helene last year. Management expects pump revenue to increase in the second half of the year as Spectrum technology gains traction, but higher production costs should limit performance in the second quarter. Its model projects revenue in this segment to decline 3% to $1.3 billion at constant exchange rates. The Healthcare Systems and Technologies segment is expected to face another weak quarter, offset by strong demand for patient support systems and significant capital equipment orders in the US, partly due to delays in the installation of first aid equipment. Management still expects the segment's performance to improve later this year as recently launched products, including Connex 360 and the Dynamo intelligent stretcher, begin to make a more significant contribution. Its model projects revenue for this segment to grow 2.9% to $795.1 million at constant currency rates. The pharmaceutical segment may still face challenges such as limited supply of injectables, weak global demand for inhalational anesthetics, and an unfavorable product mix. However, improved manufacturing efficiency, continued declines in order volumes, and strong growth in the formulation business should mitigate these negative factors to some extent. According to its model, at constant exchange rates, segment revenue will decline 3.6% to $609 million. Baxter may continue to face high production costs, tariff-related expenses, and inflationary pressure in the second quarter. Management expects this pressure to ease in the second half of the year as high-cost inventory is depleted, cost-cutting measures are implemented, and operating leverage improves thanks to a seasonal sales recovery. Therefore, adjusted earnings per share in the second quarter are likely to remain flat compared to the first quarter. Its model didn't predict that Baxter would beat earnings estimates this time. The likelihood of a beat increases when the earnings estimate deviation is positive and the Zacks Rank is a 1 (Strong Buy), 2 (Buy), or 3 (Hold). However, as you'll see below, this isn't the case for Baxter. Baxter (ESP) Earnings Estimate Variance: The earnings estimate deviation is the difference between the most accurate earnings forecast and the Zacks Consensus Estimate. Baxter's earnings estimate deviation is -0.99%. Use its earnings estimate deviation filter to find the best stocks to buy and sell before earnings releases. Baxter's stock price has risen 13.4% year-to-date, while the industry as a whole has fallen 22.5% over the same period. The S&P 500 has risen 9.3% over the same period. Here are a few healthcare stocks to watch because they have the right combination of factors to outperform expectations this earnings cycle. Cardinal Health (CAH) currently has an Earnings Expectations ESP of +1.24%, giving it a Zacks Rank of #2. The company is scheduled to report its fourth-quarter fiscal 2026 earnings on August 11th. The complete list of today's Zacks Rank #1 stocks can be found here. CAH's earnings have beaten expectations over the past four quarters, by an average of 10.27%. The Zacks Consensus Estimate is for CAH's fourth-quarter earnings per share to increase 16.4% year-over-year. Henry Shane Inc. (HSIC) currently has an estimated earnings consensus of +0.41%, giving it a Zacks Rank of #2. The company is scheduled to report second-quarter 2026 earnings on August 4. HSIC has beaten earnings estimates in three of the last four quarters and missed them in one, surpassing estimates by an average of 3.74%. The Zacks Consensus Estimate is for HSIC's second-quarter earnings per share to increase 10.9% year-over-year. Company A has beaten earnings estimates in three of the last four quarters and missed them in one quarter, beating the estimate by 1.61% on average. The Zacks Consensus Estimate is for Company A's earnings per share to increase 8% year-over-year in the third quarter of fiscal 2026. Five Zacks experts selected thousands of stocks they believed had the potential to grow by 100% or more in the coming months. Research Director Sheraz Mian selected one of these five stocks, believing it had the greatest explosive growth potential. This company targets millennials and Gen Z and generated nearly $1 billion in revenue in its most recent quarter. The recent share price drop represents an excellent entry point. While not all of its recommendations will be profitable, this stock has far greater potential than previous Zacks "Potential Doubler" stocks, such as Nano-X Imaging, which has risen 129.6% in just nine months. Get free access to our top picks and four other promising stocks. Want the latest recommendations from Zacks Investment Research? Download the "Top 7 Stocks for the Next 30 Days" report for free today. Click here to get this free report. Portions of market data provided by ICE Data Services. Portions of reference data provided by FactSet. Copyright (C) 2026 FactSet Research Systems Inc. Copyright (C) 2026 American Bankers Association. CUSIP database provided by FactSet Research Systems Inc. All rights reserved. SEC filings and other documents provided by Quartr. (C) 2026 TradingView, Inc. Post time: Jul-27-2026
Webinar - when the first surgery is not the last: adhesions and long-term strategy in HPB surgery. For many hepatobiliary surgeons, the success of an operation is measured by the outcome of the procedure itself. Yet for an increasing number of patients, the first operation is only one step in a much longer treatment journey. Patients with colorectal liver metastases, hepatocellular carcinoma and other complex hepatobiliary diseases frequently require staged procedures, repeat liver resections or further abdominal surgery. In these situations, postoperative adhesions can significantly influence future operative difficulty, prolong operating times, increase conversion rates and complicate subsequent surgical access. Despite their impact, adhesions often remain an under-recognised consideration during the initial surgical planning process. Recognising this important challenge, IHPBA and Baxter are partnering to present an educational webinar exploring the long-term implications of adhesions in liver surgery and practical strategies that may help optimise future surgical options. A practical, case-based discussion. Presented by Dr Francesca Ratti, Senior Staff Surgeon at the IRCCS San Raffaele Scientific Institute and Assistant Professor of Surgery at Vita-Salute San Raffaele University in Milan, the webinar will examine adhesions through real-world clinical scenarios rather than theory alone. Drawing on her extensive experience in minimally invasive liver surgery and complex hepatobiliary oncology, Dr Ratti will discuss how surgical history, disease setting and operative strategy influence both the development and consequences of adhesions. Participants will explore when adhesion prevention should become part of the surgical plan and how anti-adhesion technologies may contribute to facilitating future abdominal access in carefully selected patients. Learning from real-world data. An important feature of the webinar will be insights from the Italian Registry of Minimally Invasive Liver Resections, examining how previous surgery, whether open or minimally invasive, can affect operative complexity, conversion rates and decision-making during repeat liver procedures. The discussion will also focus on patients undergoing two-stage hepatectomy, repeat liver resections and multidisciplinary treatment pathways where future reintervention is anticipated, providing attendees with practical considerations that can be incorporated into everyday clinical practice. Practical takeaways for surgeons. By combining registry evidence, clinical reasoning and practical operative experience, this webinar aims to provide surgeons with a structured framework for: * Identifying patients at increased risk of adhesion-related challenges. * Recognising clinical situations where adhesion prevention strategies may be appropriate. * Understanding how previous open and minimally invasive surgery can influence future operative planning. * Incorporating long-term surgical strategy into decision-making for patients likely to require repeat abdominal procedures. As advances in hepatobiliary oncology continue to improve survival, more patients are living long enough to undergo multiple interventions over the course of their disease. This shift challenges surgeons to think beyond the immediate operation and consider how today's surgical decisions may affect tomorrow's opportunities. Join IHPBA and Baxter. Join IHPBA and Baxter on Thursday, 3 September 2026, for this timely webinar exploring how long-term planning and thoughtful adhesion management can help optimise outcomes for patients requiring repeat hepatobiliary surgery. Baxter is a registered trademark of Baxter International Inc. Published on Friday 24th July 2026
Q2 EPS forecast for Baxter International lowered by analyst. July 15, 2026 Key points. * Zacks Research lowered its Q2 2026 EPS estimate for Baxter International to $0.36 from $0.37 and kept a Strong Sell rating on the stock. * Baxter's latest quarter beat expectations, reporting $0.36 EPS versus the $0.31 consensus and $2.70 billion in revenue versus $2.62 billion expected, though earnings were down from the prior year. * Sentiment remains cautious overall: analysts now have an average rating of Reduce with a consensus price target of $19.73, while the stock recently traded above that level at $21.80. * MarketBeat previews the top five stocks to own by August 1st. Baxter International Inc. (NYSE:BAX - Free Report) - Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for shares of Baxter International in a report issued on Tuesday, July 14th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of $0.36 per share for the quarter, down from their previous estimate of $0.37. Zacks Research has a "Strong Sell" rating on the stock. The consensus estimate for Baxter International's current full-year earnings is $1.92 per share. Zacks Research also issued estimates for Baxter International's Q3 2026 earnings at $0.50 EPS, FY2026 earnings at $1.83 EPS, Q3 2027 earnings at $0.54 EPS, FY2027 earnings at $1.90 EPS and FY2028 earnings at $2.13 EPS. Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 EPS for the quarter, beating the consensus estimate of $0.31 by $0.05. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The company had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same quarter last year, the company posted $0.62 earnings per share. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. A number of other analysts have also issued reports on the company. Citigroup lowered Baxter International from a "neutral" rating to a "sell" rating and lowered their target price for the company from $19.00 to $17.00 in a report on Thursday, May 28th. The Goldman Sachs Group boosted their target price on shares of Baxter International from $17.00 to $19.00 in a research report on Friday, May 1st. Stifel Nicolaus decreased their price target on shares of Baxter International from $20.00 to $19.00 in a research report on Friday, May 1st. TD Cowen cut their price objective on shares of Baxter International from $22.00 to $20.00 in a research report on Friday, May 1st. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Baxter International in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $19.73. Discover more Derivatives Business News Baxter International stock performance. NYSE:BAX opened at $21.80 on Wednesday. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43. The firm's fifty day simple moving average is $19.93 and its 200 day simple moving average is $19.28. The firm has a market capitalization of $11.26 billion, a PE ratio of -10.23, a PEG ratio of 3.63 and a beta of 0.62. Baxter International has a 1 year low of $15.73 and a 1 year high of $29.35. Baxter International announces dividend. The business also recently declared a quarterly dividend, which was paid on Wednesday, July 1st. Shareholders of record on Friday, May 29th were given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date was Friday, May 29th. Baxter International's dividend payout ratio is -1.88%. Institutional inflows and outflows. Hedge funds and other institutional investors have recently made changes to their positions in the stock. Greenhaven Associates Inc. boosted its stake in shares of Baxter International by 70.0% in the 4th quarter. Greenhaven Associates Inc. now owns 10,693,223 shares of the medical instruments supplier's stock valued at $204,347,000 after purchasing an additional 4,404,874 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Baxter International by 477.6% during the fourth quarter. SG Americas Securities LLC now owns 1,725,251 shares of the medical instruments supplier's stock worth $32,970,000 after buying an additional 1,426,547 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Baxter International by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier's stock valued at $257,174,000 after buying an additional 972,891 shares during the period. Russell Investments Group Ltd. lifted its holdings in Baxter International by 35.6% in the fourth quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier's stock valued at $65,216,000 after buying an additional 894,761 shares during the period. Finally, Gendell Jeffrey L bought a new position in Baxter International in the fourth quarter valued at approximately $8,525,000. 90.19% of the stock is owned by institutional investors. More Baxter International news. Here are the key news stories impacting Baxter International this week: * Positive Sentiment: Baxter said it is updating its segment reporting structure and metrics, which could improve transparency around business performance and make results easier for investors to follow. Baxter International Updates Segment Reporting Structure and Metrics * Neutral Sentiment: The stock also drew attention for a technical "golden cross," where the 50-day moving average moved above the 200-day moving average, a signal some traders view as constructive. AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap * Negative Sentiment: Zacks Research downgraded Baxter International from "hold" to "strong sell," which is likely weighing on sentiment. Zacks.com downgrade * Negative Sentiment: The same analyst firm trimmed near-term and longer-term earnings forecasts for Baxter, including FY2026 EPS to $1.83 from $1.87, FY2027 to $1.90 from $1.91, and Q2/Q3 2026 estimates as well, signaling softer profit expectations. Baxter International company profile. Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide. In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Baxter International, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list. While Baxter International currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Baxter Corporation products recall; Blue cap breakage. Shazia 12 July 2026Medicine Summary. Sodium chloride injection (Baxter); Sodium chloride Irrigation; (20 mmol/L) Potassium chloride in 5% Dextrose and 0.9% Sodium chloride injection; Lactated Ringer's injection Health products - Packaging What to do Consult your health care professional if you have any health concerns. Healthcare Showing 1 to 4 of 4 entries | Baxter Corporation | 0.9% Sodium chloride injection, USP | DIN 00060208 | Solution | Sodium chloride 900 mg/ 100 mL | W6A14B0, W6B04B0, W6C05B0, W6C06B0, W6C11B0, W5L16M0, W5L16M0A, W5L16M0S, W6A14A0, W6A16A0, W6A18A0, W6A28M0, W6A28M0A, W6B05M0, W6B05M0A, W6B08A0, W6B21A1 | | Baxter Corporation | 0.9% Sodium chloride Irrigation, USP | DIN 00786160 | Solution | Sodium chloride 900 mg/ 100 mL | W6C11T1 | | Baxter Corporation | (20 mmol/L) Potassium chloride in 5% Dextrose and 0.9% Sodium chloride injection, USP | DIN 00786292 | Solution | Dextrose 5 g / 100 mL Potassium chloride 150 mg / 100 mL Sodium Chloride 900 mg / 100 mL | W6C05A1 | | Baxter Corporation | Lactated Ringer's injection, USP | DIN 00061085 | Solution | Calcium chloride 20 mg / 100 mL Potassium chloride 30 mg / 100 mL Sodium chloride 600 mg / 100 mL Sodium lactate 310 mg / 100 mL | W6C05A0 | Issue. Blue Caps Enhanced Closures (blue tip protectors) may break apart in affected lots. What you should do. * Verify if your product is affected. * Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. * Contact the recalling firm if you have any questions about the recall. * Report any health product related side effects to Health Canada. * Report any other health product safety complaints to Health Canada. Report a side effect. For industry information about COVID-19, visit its COVID-19 health product industry section. Anyone can report a side effect to a health or cannabis product. Your report can help make these products safer for all Canadians. Report the issue as soon as possible after the reaction or problem occurred. You should do this even if you are not sure if a particular health or cannabis product was the cause. Additional news Every report counts. Together they tell a story. Report! It's important to report side effects, injuries and other product-related health and safety concerns so Eawaz can make important safety decisions about the products you use. If you're a health or industry professional, please see adverse reaction reporting for specific products. If you're a consumer, choose the category below that best describes the product you want to report. You can find examples of each kind of product to help you choose. Important! If you're suffering from a side effect or serious injury related to a product, you should contact your doctor, health professional, local health authority or provincial poison control centre. Examples of health product complaints. The following are examples of typical health product complaints: * counterfeit products * unauthorized sale of health products * product mix-ups and incorrect components * particulate matter, foreign materials and contamination * labelling errors * concerns about the safety of a medical device or its ability to perform as claimed * concerns with the conduct of a clinical trial or the health product of a clinical trial * violations of the Food and Drugs Act and associated Regulations related to health products When reporting a complaint, you should provide certain information to help ROEB assess what priority to assign your complaint. This will also help reduce delays in taking the necessary compliance action(s). Please provide the following information: * your contact information * response to the privacy notice questions in the complaint form * a description of the issue * the product's name * where the health product was advertised, purchased, obtained, used or seen available for sale * the product licence number, catalogue or model number, lot number, expiry date (if available) Latest news & talk shows in Urdu & Punjabi for GTA South Asian community. Listen and watch live on 770AM radio & eawaz TV. Get alerts on all-in-one eawaz Official app.